CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: CFI-400945|DRUG: Durvalumab
Sponsor: Canadian Cancer Trials Group
Collaborators: AstraZeneca|University Health Network, Toronto